Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prediction of Platinum Resistance and Prognosis in Patients with High-grade Serous Ovarian Cancer Based on MRI Habitat Imaging and Radiopathomics

NCT06787170 is registered in ClinicalTrials.gov with The First People's Hospital of Yunnan as lead sponsor.

NCT NCT06787170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06787170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prediction of Platinum Resistance and Prognosis in Patients with High-grade Serous Ovarian Cancer Based on MRI Habitat Imaging and Radiopathomics
Lead sponsor
The First People's Hospital of Yunnan
Phase
Observational
Overall status
Completed
Start date
November 1, 2022
Completion date
May 31, 2024
Enrollment
1,129 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade serous ovarian cancer (hgsoc)